1-13 of 13
Authors: David A. Cooper
Journal Article
Risk of Suicidal Behavior With Use of Efavirenz: Results from the Strategic Timing of Antiretroviral Treatment Trial Free
Clinical Infectious Diseases, Volume 67, Issue 3, 1 August 2018, Pages 420–429, https://doi.org/10.1093/cid/ciy051
Published: 12 March 2018
Journal Article
Cerebrospinal Fluid Exposure of Efavirenz and Its Major Metabolites When Dosed at 400 mg and 600 mg Once Daily: A Randomized Controlled Trial Get access
Clinical Infectious Diseases, Volume 60, Issue 7, 1 April 2015, Pages 1026–1032, https://doi.org/10.1093/cid/ciu976
Published: 11 December 2014
Journal Article
Efavirenz versus Boosted Atazanavir or Zidovudine and Abacavir in Antiretroviral Treatment-Naive, HIV-Infected Subjects: Week 48 Data from the Altair Study Get access
Clinical Infectious Diseases, Volume 51, Issue 7, 1 October 2010, Pages 855–864, https://doi.org/10.1086/656363
Published: 01 October 2010
Journal Article
Does Choice of Combination Antiretroviral Therapy (cART) Alter Changes in Cerebral Function Testing after 48 Weeks in Treatment-Naive, HIV-1–Infected Individuals Commencing cART? A Randomized, Controlled Study Get access
Clinical Infectious Diseases, Volume 50, Issue 6, 15 March 2010, Pages 920–929, https://doi.org/10.1086/650743
Published: 15 March 2010
Journal Article
Long-Term Efficacy and Safety of Raltegravir Combined with Optimized Background Therapy in Treatment-Experienced Patients with Drug-Resistant HIV Infection: Week 96 Results of the BENCHMRK 1 and 2 Phase III Trials Get access
Clinical Infectious Diseases, Volume 50, Issue 4, 15 February 2010, Pages 605–612, https://doi.org/10.1086/650002
Published: 15 February 2010
Journal Article
Simplification of Antiretroviral Therapy with Tenofovir-Emtricitabine or Abacavir-Lamivudine: A Randomized, 96-Week Trial Get access
Clinical Infectious Diseases, Volume 49, Issue 10, 15 November 2009, Pages 1591–1601, https://doi.org/10.1086/644769
Published: 15 November 2009
Journal Article
Predictors of Virological Outcome and Safety in Primary HIV Type 1–Infected Patients Initiating Quadruple Antiretroviral Therapy: QUEST GW PROB3005 Get access
Clinical Infectious Diseases, Volume 45, Issue 3, 1 August 2007, Pages 381–390, https://doi.org/10.1086/519428
Published: 01 August 2007
Journal Article
The Safety, Efficacy, and Pharmacokinetic Profile of a Switch in Antiretroviral Therapy to Saquinavir, Ritonavir, and Atazanavir Alone for 48 Weeks and a Switch in the Saquinavir Formulation Get access
Clinical Infectious Diseases, Volume 44, Issue 11, 1 June 2007, Pages 1475–1483, https://doi.org/10.1086/517507
Published: 01 June 2007
Journal Article
Efficacy of the Protease Inhibitors Tipranavir plus Ritonavir in Treatment-Experienced Patients: 24-Week Analysis from the RESIST-1 Trial Get access
Clinical Infectious Diseases, Volume 43, Issue 10, 15 November 2006, Pages 1337–1346, https://doi.org/10.1086/508353
Published: 15 November 2006
Journal Article
The Modern ART of HIV Infection Management: Towards a Tailored Approach to Maximize CD4 T Cell Reconstitution Get access
Clinical Infectious Diseases, Volume 41, Issue 3, 1 August 2005, Pages 373–375, https://doi.org/10.1086/431489
Published: 01 August 2005
Journal Article
A Prospective, Randomized Trial of Structured Treatment Interruption for Patients with Chronic HIV Type 1 Infection Get access
Clinical Infectious Diseases, Volume 40, Issue 4, 15 February 2005, Pages 594–600, https://doi.org/10.1086/427695
Published: 15 February 2005
Journal Article
Severity and Prognosis of Acute Human Immunodeficiency Virus Type 1 Illness: A Dose-Response Relationship Get access
Clinical Infectious Diseases, Volume 26, Issue 2, February 1998, Pages 323–329, https://doi.org/10.1086/516289
Published: 01 February 1998
Journal Article
Acute Human Immunodeficiency Virus Type 1 Disease as a Mononucleosis-Like Illness: Is the Diagnosis Too Restrictive? Get access
Clinical Infectious Diseases, Volume 24, Issue 5, May 1997, Pages 965–970, https://doi.org/10.1093/clinids/24.5.965
Published: 01 May 1997
